Logo image of GLPG

GALAPAGOS NV-SPON ADR (GLPG) Stock Fundamental Analysis

NASDAQ:GLPG - Nasdaq - US36315X1019 - ADR - Currency: USD

26.74  +0.01 (+0.04%)

Premarket: 26.9 +0.16 (+0.6%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to GLPG. GLPG was compared to 571 industry peers in the Biotechnology industry. GLPG scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. GLPG does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

In the past year GLPG was profitable.
GLPG had a negative operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: GLPG reported negative net income in multiple years.
In the past 5 years GLPG reported 4 times negative operating cash flow.
GLPG Yearly Net Income VS EBIT VS OCF VS FCFGLPG Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 1B 2B 3B

1.2 Ratios

With an excellent Return On Assets value of 6.24%, GLPG belongs to the best of the industry, outperforming 95.72% of the companies in the same industry.
GLPG's Return On Equity of 9.10% is amongst the best of the industry. GLPG outperforms 95.19% of its industry peers.
Industry RankSector Rank
ROA 6.24%
ROE 9.1%
ROIC N/A
ROA(3y)-0.58%
ROA(5y)-0.92%
ROE(3y)-1.65%
ROE(5y)-2.24%
ROIC(3y)N/A
ROIC(5y)N/A
GLPG Yearly ROA, ROE, ROICGLPG Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -10 -20 -30

1.3 Margins

Looking at the Profit Margin, with a value of 51.70%, GLPG belongs to the top of the industry, outperforming 99.11% of the companies in the same industry.
GLPG does not have Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) 51.7%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
GLPG Yearly Profit, Operating, Gross MarginsGLPG Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 100 -100

More info and screens

5

2. Health

2.1 Basic Checks

GLPG does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for GLPG remains at a similar level compared to 1 year ago.
GLPG has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, GLPG has an improved debt to assets ratio.
GLPG Yearly Shares OutstandingGLPG Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M
GLPG Yearly Total Debt VS Total AssetsGLPG Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2B 4B 6B

2.2 Solvency

Based on the Altman-Z score of 1.61, we must say that GLPG is in the distress zone and has some risk of bankruptcy.
GLPG has a Altman-Z score of 1.61. This is in the better half of the industry: GLPG outperforms 69.34% of its industry peers.
A Debt/Equity ratio of 0.00 indicates that GLPG is not too dependend on debt financing.
With a Debt to Equity ratio value of 0.00, GLPG perfoms like the industry average, outperforming 46.35% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 1.61
ROIC/WACCN/A
WACC7.85%
GLPG Yearly LT Debt VS Equity VS FCFGLPG Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 1B 2B

2.3 Liquidity

A Current Ratio of 10.13 indicates that GLPG has no problem at all paying its short term obligations.
GLPG's Current ratio of 10.13 is amongst the best of the industry. GLPG outperforms 80.39% of its industry peers.
GLPG has a Quick Ratio of 9.95. This indicates that GLPG is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 9.95, GLPG belongs to the top of the industry, outperforming 80.04% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 10.13
Quick Ratio 9.95
GLPG Yearly Current Assets VS Current LiabilitesGLPG Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 1B 2B 3B 4B 5B

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 236.12% over the past year.
The Revenue for GLPG has decreased by -16.23% in the past year. This is quite bad
Measured over the past years, GLPG shows a decrease in Revenue. The Revenue has been decreasing by -2.02% on average per year.
EPS 1Y (TTM)236.12%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-297.44%
Revenue 1Y (TTM)-16.23%
Revenue growth 3Y-18.51%
Revenue growth 5Y-2.02%
Sales Q2Q%-50.14%

3.2 Future

GLPG is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -28.71% yearly.
Based on estimates for the next years, GLPG will show a decrease in Revenue. The Revenue will decrease by -8.54% on average per year.
EPS Next Y-140.29%
EPS Next 2Y-47.28%
EPS Next 3Y-34.96%
EPS Next 5Y-28.71%
Revenue Next Year-46.03%
Revenue Next 2Y-29.27%
Revenue Next 3Y-20.55%
Revenue Next 5Y-8.54%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
GLPG Yearly Revenue VS EstimatesGLPG Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 200M 400M 600M 800M 1B
GLPG Yearly EPS VS EstimatesGLPG Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 2 -2 4 -4

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

Based on the Price/Earnings ratio of 8.10, the valuation of GLPG can be described as reasonable.
GLPG's Price/Earnings ratio is rather cheap when compared to the industry. GLPG is cheaper than 98.22% of the companies in the same industry.
GLPG's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 29.62.
The Forward Price/Earnings Ratio is negative for GLPG. No positive earnings are expected for the next year.
Industry RankSector Rank
PE 8.1
Fwd PE N/A
GLPG Price Earnings VS Forward Price EarningsGLPG Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 -40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
GLPG Per share dataGLPG EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 20 30 40

4.3 Compensation for Growth

A cheap valuation may be justified as GLPG's earnings are expected to decrease with -34.96% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-47.28%
EPS Next 3Y-34.96%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for GLPG!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

GALAPAGOS NV-SPON ADR

NASDAQ:GLPG (2/21/2025, 8:23:56 PM)

Premarket: 26.9 +0.16 (+0.6%)

26.74

+0.01 (+0.04%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-12 2025-02-12/amc
Earnings (Next)04-23 2025-04-23
Inst Owners48.62%
Inst Owner Change-93.81%
Ins Owners0.01%
Ins Owner ChangeN/A
Market Cap1.76B
Analysts52
Price Target34.7 (29.77%)
Short Float %3.48%
Short Ratio6.5
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)55.89%
Min EPS beat(2)-52.97%
Max EPS beat(2)164.74%
EPS beat(4)3
Avg EPS beat(4)331%
Min EPS beat(4)-52.97%
Max EPS beat(4)1052.58%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-4.64%
Min Revenue beat(2)-15.5%
Max Revenue beat(2)6.22%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-2.65%
PT rev (3m)-19.64%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-295.18%
EPS NY rev (1m)-28.66%
EPS NY rev (3m)-30.3%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-2.57%
Revenue NY rev (1m)-6.99%
Revenue NY rev (3m)-3.62%
Valuation
Industry RankSector Rank
PE 8.1
Fwd PE N/A
P/S 3.34
P/FCF N/A
P/OCF N/A
P/B 0.59
P/tB 0.64
EV/EBITDA N/A
EPS(TTM)3.3
EY12.34%
EPS(NY)-0.58
Fwd EYN/A
FCF(TTM)-6.54
FCFYN/A
OCF(TTM)-5.2
OCFYN/A
SpS8
BVpS45.46
TBVpS41.6
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 6.24%
ROE 9.1%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) 51.7%
GM N/A
FCFM N/A
ROA(3y)-0.58%
ROA(5y)-0.92%
ROE(3y)-1.65%
ROE(5y)-2.24%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.12
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 193.36%
Cap/Sales 16.75%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 10.13
Quick Ratio 9.95
Altman-Z 1.61
F-Score5
WACC7.85%
ROIC/WACCN/A
Cap/Depr(3y)89.21%
Cap/Depr(5y)224.68%
Cap/Sales(3y)10.26%
Cap/Sales(5y)10.63%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)236.12%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-297.44%
EPS Next Y-140.29%
EPS Next 2Y-47.28%
EPS Next 3Y-34.96%
EPS Next 5Y-28.71%
Revenue 1Y (TTM)-16.23%
Revenue growth 3Y-18.51%
Revenue growth 5Y-2.02%
Sales Q2Q%-50.14%
Revenue Next Year-46.03%
Revenue Next 2Y-29.27%
Revenue Next 3Y-20.55%
Revenue Next 5Y-8.54%
EBIT growth 1Y-26.52%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year70.19%
EBIT Next 3Y4.12%
EBIT Next 5Y-2.6%
FCF growth 1Y23.13%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y32.39%
OCF growth 3YN/A
OCF growth 5YN/A